NTHI (NeOnc Technologies Holdings) Scaled Net Operating Assets: -4.61 (As of Mar. 2026)


NTHI NeOnc Technologies Holdings Inc NTHI
7 GF Score
Price $4.41
! 1 Warning Sign
View Full Analysis

What is NeOnc Technologies Holdings Scaled Net Operating Assets?

NeOnc Technologies Holdings NTHI -0.90% 7 Scaled Net Operating Assets is -4.61 as of Mar. 2026. GuruFocus rates NTHI with a GF Score™ of 7/100. The stock has 1 warning sign investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

NeOnc Technologies Holdings's operating assets for the quarter that ended in Mar. 2026 was $3.19 Mil. NeOnc Technologies Holdings's operating liabilities for the quarter that ended in Mar. 2026 was $16.22 Mil. NeOnc Technologies Holdings's Total Assets for the quarter that ended in Dec. 2025 was $2.82 Mil. Therefore, NeOnc Technologies Holdings's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was -4.61.

NeOnc Technologies Holdings Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for NeOnc Technologies Holdings's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeOnc Technologies Holdings Scaled Net Operating Assets Chart

NeOnc Technologies Holdings Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Scaled Net Operating Assets
-46.66 -67.44 -10.17 -4.38 -3.29

NeOnc Technologies Holdings Quarterly Data
Dec21 Sep22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.41 -1.37 -2.76 -2.76 -4.61

NTHI vs GUTS, PEPG, ENGN: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, NeOnc Technologies Holdings's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeOnc Technologies Holdings Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeOnc Technologies Holdings's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where NeOnc Technologies Holdings's Scaled Net Operating Assets falls into.


NTHI
7GF Score
NeOnc Technologies Holdings Inc NTHI
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeOnc Technologies Holdings Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

NeOnc Technologies Holdings's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2025 )
=(Operating Assets (A: Dec. 2025 )-Operating Liabilities (A: Dec. 2025 ))/Total Assets (A: Dec. 2024 )
=(2.765-14.017)/3.417
=-3.29

where

Operating Assets(A: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=2.824 - 0.059
=2.765

Operating Liabilities(A: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=20.331 - 0.291 - 6.023
=14.017

NeOnc Technologies Holdings's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2026 )
=(Operating Assets (Q: Mar. 2026 )-Operating Liabilities (Q: Mar. 2026 ))/Total Assets (Q: Dec. 2025 )
=(3.191-16.215)/2.824
=-4.61

where

Operating Assets(Q: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=3.33 - 0.139
=3.191

Operating Liabilities(Q: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=16.561 - 0.274 - 0.072
=16.215

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of -4.61 mean?
NeOnc Technologies Holdings (NTHI) has a Scaled Net Operating Assets of -4.61 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on NeOnc Technologies Holdings and its competitors.
Is NeOnc Technologies Holdings' Scaled Net Operating Assets too high?
NeOnc Technologies Holdings' current Scaled Net Operating Assets is -4.61. Overall, NeOnc Technologies Holdings has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does NeOnc Technologies Holdings' Scaled Net Operating Assets compare to GUTS and PEPG?
NeOnc Technologies Holdings' Scaled Net Operating Assets of -4.61 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on NeOnc Technologies Holdings and its competitors. NeOnc Technologies Holdings's current Scaled Net Operating Assets is -4.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeOnc Technologies Holdings stock overvalued right now?
NeOnc Technologies Holdings (NTHI) has a current Scaled Net Operating Assets of -4.61. The current Scaled Net Operating Assets is -4.61. NeOnc Technologies Holdings' overall GF Score™ is 7/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For NeOnc Technologies Holdings (NTHI), the current Scaled Net Operating Assets is -4.61 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NeOnc Technologies Holdings Business Description

Address 23975 Park Sorrento, Suite 205, Calabasas, CA, USA, 91302
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.
7GF Score

Get the complete analysis for NTHI

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.41
Price